Several successive generations of TKIs have been approved in an effort to address the BCR::ABL1 point mutation resistance vulnerabilities of CML patients, however, predicting BP progression and effectively treating BP patients with resistance remains an area of clinical challenge. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.